The earnings call reflected strong commercial performance and strategic progress, especially with the success of BRIUMVI and advancements in its subcutaneous version. However, increased operating expenses and potential challenges from payer preferences for subcutaneous therapies were noted.

Company Guidance -

Q3 2025

During the second quarter of 2025 earnings call, TG Therapeutics provided an update on their financial and operational performance, highlighting the robust momentum of their flagship product, BRIUMVI. The company reported U.S. net sales for BRIUMVI at approximately $139 million for Q2, marking a 91% year-over-year increase and a 16% growth over the previous quarter. They noted that nearly one-third of new IV anti-CD20 patients are prescribed BRIUMVI, reflecting significant progress towards their goal of making it the leading anti-CD20 therapy for relapsing multiple sclerosis. The company raised their full-year U.S. BRIUMVI net revenue guidance from $560-$570 million to $575 million, anticipating stronger growth from Q3 to Q4. They also discussed the ongoing development of a subcutaneous version of BRIUMVI and their plans for a pivotal Phase III trial to assess its efficacy compared to the IV formulation. Additionally, TG Therapeutics reported a GAAP net income of $28.2 million for the quarter and ended Q2 with approximately $279 million in cash and investments, maintaining a strong capital position for future investments.

Strong Commercial Performance

U.S. net sales for BRIUMVI in Q2 totaled approximately $139 million, ahead of internal expectations, marking the highest number of new patient enrollments since launch.

Subcutaneous BRIUMVI Development

Initiating patient enrollment into pivotal Phase III trial for subcutaneous BRIUMVI, with plans to file a BLA in 2027 and potential launch in 2028.

Revenue Growth

Total revenue of $141.1 million for Q2 2025, representing a 91% increase compared to the same period last year and 16% growth over Q1 2025.

Net Income Increase

Reported GAAP net income of $28.2 million, or $0.17 per diluted share for Q2 2025, compared to $6.9 million, or $0.04 per diluted share in Q2 2024.

Market Share Growth

BRIUMVI is capturing nearly 1/3 of new IV anti-CD20 therapy patient starts, indicating significant market penetration.

TG Therapeutics (TGTX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TGTX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	0.22 / -	0.02	―	―	―
Aug 04, 2025	2025 (Q2)	0.21 / 0.17	0.04	325.00% (+0.13)	―
May 05, 2025	2025 (Q1)	0.17 / 0.03	-0.07	142.86% (+0.10)	―
Mar 03, 2025	2024 (Q4)	0.16 / 0.15	-0.09	266.67% (+0.24)	―
Nov 04, 2024	2024 (Q3)	0.03 / 0.02	0.73	-97.26% (-0.71)	―
Aug 06, 2024	2024 (Q2)	-0.05 / 0.04	-0.34	111.76% (+0.38)	―
May 01, 2024	2024 (Q1)	-0.06 / -0.07	-0.28	75.00% (+0.21)	―
Feb 28, 2024	2023 (Q4)	-0.10 / -0.09	-0.39	76.92% (+0.30)	―
Nov 01, 2023	2023 (Q3)	0.06 / 0.73	-0.26	380.77% (+0.99)	―
Aug 01, 2023	2023 (Q2)	-0.25 / -0.34	-0.3	-13.33% (-0.04)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

TGTX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 04, 2025	$35.02	$28.72	-17.99%
May 05, 2025	$43.44	$37.68	-13.26%
Mar 03, 2025	$30.09	$34.42	+14.39%
Nov 04, 2024	$26.90	$24.36	-9.44%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does TG Therapeutics (TGTX) report earnings?

TG Therapeutics (TGTX) is schdueled to report earning on Oct 30, 2025, TBA (Confirmed).

What is TG Therapeutics (TGTX) earnings time?

TG Therapeutics (TGTX) earnings time is at Oct 30, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is TGTX EPS forecast?

TGTX EPS forecast for the fiscal quarter 2025 (Q3) is 0.22.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing